Keyphrases
Hematological Malignancies
100%
Lung Cancer
100%
Human Cancer
100%
Programmed Death-ligand 1 (PD-L1)
100%
Cancer Therapy
100%
Immune Checkpoint Blockade
100%
Cancer Malignancy
100%
PD-L2
66%
Clinical Efficacy
33%
Tumor
33%
Immune Memory
33%
Therapeutic Trial
33%
Conventional Chemotherapy
33%
Immune Evasion
33%
T Cell Activation
33%
Immune Checkpoint
33%
Less Toxic
33%
Refractory Disease
33%
B7-H3
33%
B7-1
33%
Human Lung Cancer
33%
B7 Family
33%
B7-2
33%
Cancer Hallmarks
33%
Antibody Blocking
33%
Tumor Immune Evasion
33%
HHLA2
33%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
33%
Checkpoint Blockade
33%
Medicine and Dentistry
Cancer Therapy
100%
Lung Cancer
100%
Programmed Death-Ligand 1
100%
Hematologic Malignancy
100%
Immune Checkpoint Blockade
100%
Malignant Neoplasm
50%
T Cell
50%
Combination Therapy
50%
Cell Function
50%
Neoplasm
50%
Cancer
50%
Immunological Memory
50%
CTLA-4
50%
Immune Evasion
50%
Tumor Escape
50%
Blocking Antibody
50%
Diseases
50%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Lung Cancer
100%
Hematologic Malignancy
100%
Neoplasm
100%
Chemotherapy
50%
Combination Therapy
50%
Blocking Antibody
50%
Cytotoxic T Lymphocyte Antigen 4
50%
Diseases
50%
Immunology and Microbiology
Immune Checkpoint Blockade
100%
Programmed Death-Ligand 1
100%
Blocking Antibody
50%
Cell Function
50%
Immunological Memory
50%
Immune Evasion
50%
Tumor Escape
50%
CTLA-4
50%
T Cell
50%